开云app官网登录入口网页版-官方正版

#uPAR#

12篇内容 | 912人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2024595, encodeId=76a8202459552, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=Nat Med：在血浆suPAR水平指导下阿那白滞素对COVID-19的早期治疗, objectType=article, longId=216713, objectId=c12f216e1371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c12f216e1371, replyNumber=0, likeNumber=75, createdTime=2022-04-11, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c12f216e1371, moduleTitle=Nat Med：在血浆suPAR水平指导下阿那白滞素对COVID-19的早期治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c12f216e1371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024594, encodeId=cc5b2024594a6, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, objectType=article, longId=201449, objectId=7c8f201449ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8f201449ff, replyNumber=0, likeNumber=71, createdTime=2021-01-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8f201449ff, moduleTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7c8f201449ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024592, encodeId=1b7920245925d, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=AJKD：儿童血浆suPAR与CKD进展, objectType=article, longId=187349, objectId=145a18e34936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145a18e34936, replyNumber=0, likeNumber=82, createdTime=2020-07-08, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145a18e34936, moduleTitle=AJKD：儿童血浆suPAR与CKD进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=145a18e34936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024593, encodeId=d768202459348, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=J Periodontal Res：健康和牙周炎患者唾液及龈沟液中可溶性Urokinase Plasminogen Activator Receptor (suPAR), galectin-1和TNF-α表达水平评估, objectType=article, longId=192004, objectId=365e192004a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365e192004a4, replyNumber=0, likeNumber=126, createdTime=2020-07-17, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365e192004a4, moduleTitle=J Periodontal Res：健康和牙周炎患者唾液及龈沟液中可溶性Urokinase Plasminogen Activator Receptor (suPAR), galectin-1和TNF-α表达水平评估, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=365e192004a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024589, encodeId=ce4b202458942, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, objectType=article, longId=122620, objectId=45fb122620ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45fb122620ba, replyNumber=0, likeNumber=90, createdTime=2018-05-11, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45fb122620ba, moduleTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=45fb122620ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024591, encodeId=3cad202459194, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=CLIN CANCER RES：头颈部鳞状细胞癌患者分子改变情况及Buparlisib疗效, objectType=article, longId=140468, objectId=9e50140468bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e50140468bb, replyNumber=0, likeNumber=90, createdTime=2018-06-16, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e50140468bb, moduleTitle=CLIN CANCER RES：头颈部鳞状细胞癌患者分子改变情况及Buparlisib疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9e50140468bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024590, encodeId=2d29202459084, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, objectType=article, longId=124477, objectId=e6f71244e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71244e794, replyNumber=0, likeNumber=72, createdTime=2018-03-08, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71244e794, moduleTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e6f71244e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024587, encodeId=6e03202458ea7, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=Lancet Oncol：Buparlisib联合内分泌治疗HR+/HER2-患者带来生存改善, objectType=article, longId=101598, objectId=f295101598ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f295101598ae, replyNumber=0, likeNumber=82, createdTime=2017-11-27, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f295101598ae, moduleTitle=Lancet Oncol：Buparlisib联合内分泌治疗HR+/HER2-患者带来生存改善, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f295101598ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024588, encodeId=f09920245889b, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=Nature Medicine：足细胞suPAR、APOL1变异和αvβ3整合素三复合体对介导了慢性肾脏病！, objectType=article, longId=103537, objectId=5d8d10353e86, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d8d10353e86, replyNumber=0, likeNumber=73, createdTime=2017-10-30, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d8d10353e86, moduleTitle=Nature Medicine：足细胞suPAR、APOL1变异和αvβ3整合素三复合体对介导了慢性肾脏病！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5d8d10353e86)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=NEJM：高水平的血液循环因子suPAR可增加慢性肾病的发病风险, objectType=article, longId=58440, objectId=3c3458440f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c3458440f4, replyNumber=0, likeNumber=73, createdTime=2015-12-05, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c3458440f4, moduleTitle=NEJM：高水平的血液循环因子suPAR可增加慢性肾病的发病风险, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3c3458440f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024585, encodeId=57c520245855d, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠, objectType=article, longId=33711, objectId=ee1e33e11fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee1e33e11fe, replyNumber=0, likeNumber=68, createdTime=2014-06-04, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee1e33e11fe, moduleTitle=JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ee1e33e11fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024584, encodeId=bc3120245844e, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, objectTitle=JASN：血液循环因子suPAR或与引发肾衰竭原因相关联, objectType=article, longId=18261, objectId=4e8118261a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e8118261a0, replyNumber=0, likeNumber=85, createdTime=2014-03-24, rootId=0, userName=chenhongpeng, userId=1777154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e8118261a0, moduleTitle=JASN：血液循环因子suPAR或与引发肾衰竭原因相关联, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4e8118261a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

uPAR

2020-05-29

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

Nat Med：在血浆suPAR水平指导下阿那白滞素对COVID-19的早期治疗

2022-04-11

智智灵药 (审核中...)

前往app查看评论内容

#uPAR#

Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后

2021-01-03

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

AJKD：儿童血浆suPAR与CKD进展

2020-07-08

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

J Periodontal Res：健康和牙周炎患者唾液及龈沟液中可溶性Urokinase Plasminogen Activator Receptor (suPAR), galectin-1和TNF-α表达水平评估

2020-07-17

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。

2018-05-11

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

CLIN CANCER RES：头颈部鳞状细胞癌患者分子改变情况及Buparlisib疗效

2018-06-16

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌

2018-03-08

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

Lancet Oncol：Buparlisib联合内分泌治疗HR+/HER2-患者带来生存改善

2017-11-27

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

Nature Medicine：足细胞suPAR、APOL1变异和αvβ3整合素三复合体对介导了慢性肾脏病！

2017-10-30

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

NEJM：高水平的血液循环因子suPAR可增加慢性肾病的发病风险

2015-12-05

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠

2014-06-04

chenhongpeng (审核中...)

前往app查看评论内容

#uPAR#

JASN：血液循环因子suPAR或与引发肾衰竭原因相关联

2014-03-24

科室
- - 订阅+
  - 更多科室
工具
服务